Fox Chase Cancer Center News

PHILADELPHIA (December 16, 2020)—A team of scientists from Fox Chase Cancer Center received a pilot award from the Melanoma Research Alliance (MRA) for a research project that will investigate a new drug target for the treatment of melanoma that combines aspects of epigenetics and immunotherapy.

PHILADELPHIA (December 8, 2020) – Researchers from Fox Chase Cancer Center have recently publish a series of collaborative studies that could help facilitate the development of new therapeutic agents for cancer treatment by altering integrin activity.

PHILADELPHIA (December 7, 2020)—Namrata (Neena) Vijayvergia, MD, assistant chief of gastrointestinal medical oncology at Fox Chase Cancer Center, was recently named a 2020 recipient of the 40 Under 40 in Cancer Award.

PHILADELPHIA (December 7, 2020) – Y. Lynn Wang, MD, PhD, FACP, a professor in the Department of Pathology and Blood Cell Development and Function program at Fox Chase Cancer Center, recently published a comprehensive review of molecular biomarkers in chronic lymphocytic leukemia (CLL), the most common leukemia in adults in the United States.

PHILADELPHIA (December 3, 2020)—Researchers at Fox Chase Cancer Center recently published new data showing that patients with head and neck cancer (HNC) recur just weeks after a complete operation at an under-appreciated rate and that this is associated with poor survival outcomes.

PHILADELPHIA (December 2, 2020)—In a recently published study, researchers at Fox Chase Cancer Center found that more elderly patients with localized head and neck cancer received multidisciplinary care compared with patients with advanced-stage disease.

PHILADELPHIA (November 30, 2020)–Researchers at Fox Chase Cancer Center have published a letter cautioning that website terms of use may limit how researchers can use online data, particularly with respect to online physician review information. Websites may require researchers to obtain permission to use online resources in research.

PHILADELPHIA (November 25, 2020)—In a recent study, researchers at Fox Chase Cancer Center used a new screening method to identify a previously unrecognized mechanism for resistance and responsiveness in Hodgkin lymphoma models being treated with brentuximab vedotin, also known by its brand name, Adcetris.